On this week’s episode of Biotech Hangout, guest Neil Kumar (CEO of BridgeBio) joins hosts Daphne Zohar, Brad Loncar, Tim Opler, Bruce Booth and Brian Skorney to discuss BridgeBio’s long awaited, positive Phase 3 transthyretin amyloid cardiomyopathy (ATTR-CM) data, including the company’s ups and downs and some leadership lessons along with the benefits of diversification. The hosts also cover the Acumen Pharmaceuticals and Eli Lilly positive Alzheimer’s data, in addition to questions around safety for eye disease trials related to Apellis’ Syfovre and Horizon Therapeutics’ Tepezza. With a news heavy week, the group also discusses data integrity issues (including the Marc Tessier-Lavigne case), the impact of priority review vouchers and deals/M&A. *This episode aired on July 21, 2023*